Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 13/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 12/20 | 0.46 |
| ▸ | GNAI1 | P63096 | 12/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20626600 | 1.00 | GNAO1 (0.46) | GNAO1GNAI3GNAI1EPHX1 | |
| SCHEMBL20306106 | 1.00 | GNAO1 (0.46) | GNAO1GNAI3GNAI1EPHX1 | |
| SCHEMBL18922334 | 1.00 | GNAO1 (0.46) | GNAO1GNAI3GNAI1EPHX1 | |
| SCHEMBL18557836 | 1.00 | GNAO1 (0.46) | GNAO1GNAI3GNAI1EPHX1 | |
| SCHEMBL20093568 | 1.00 | GNAO1 (0.46) | GNAO1GNAI3GNAI1EPHX1 | |
| SCHEMBL23709640 | 0.98 | GNAO1 (0.44) | GNAO1GNAI3GNAI1EPHX1 | |
| SCHEMBL20004213 | 0.98 | GNAO1 (0.44) | GNAO1GNAI3GNAI1EPHX1 | |
| SCHEMBL19772438 | 0.96 | GNAO1 (0.43) | GNAO1GNAI3GNAI1EPHX1 | |
| SCHEMBL21703732 | 0.96 | GNAO1 (0.42) | GNAO1GNAI3GNAI1EPHX1 | |
| SCHEMBL25018587 | 0.94 | GNAO1 (0.41) | GNAO1GNAI3GNAI1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086757-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086757-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | JAK1, JAK2, JAK3 | GNAO1 1925/4885GNAI3 2275/4885GNAI1 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.